Triplet Therapeutics develops and commercializes ribonucleic acid targeted therapeutics for the treatment of Huntington's disease... Read more
Triplet Therapeutics develops and commercializes ribonucleic acid targeted therapeutics for the treatment of Huntington's disease... Read more
2018
PrivateIndependent Company
News
Oct 12, 2022
Endpoints News
TRIPLET: Atlas-backed biotech focused on Huntington's disease shuts down less than three years after launch
Apr 27, 2021
Business Wire
Press Release: Triplet Therapeutics : Triplet Therapeutics Presents Preclinical Data for TTX-3360, Announces Equity Pledge at the CHDI Foundation's 16th Annual HD Therapeutics Conference
Mar 25, 2021
Business Wire
Press Release: Triplet Therapeutics : Triplet Therapeutics to Present at Upcoming Events
Nov 17, 2020
Boston Citybizlist
Triplet Therapeutics: Triplet Therapeutics Appoints Kathy Biberstein, J.D., and Stephen Webster to Board
Nov 16, 2020
MarketScreener
Triplet Therapeutics: Triplet Therapeutics to Present at Stifel Virtual Healthcare Conference
Nov 12, 2020
MarketScreener
Triplet Therapeutics: Triplet Therapeutics Completes Enrollment of SHIELD HD Natural History Study of Huntington's Disease
Aug 18, 2020
MarketScreener
Triplet Therapeutics: Triplet Therapeutics Announces Participation in Natural History Study of Myotonic Dystrophy Type 1
Aug 04, 2020
MarketScreener
Triplet Therapeutics: Triplet Therapeutics To Present at Upcoming Events
Jul 23, 2020
FierceBiotech
Triplet Therapeutics: Triplet Therapeutics nabs Scholar Rock R&D exec as new CSO
Jul 21, 2020
Business Wire
Press Release: Triplet Therapeutics : Triplet Therapeutics Selects Clinical Candidate for Novel Treatment of Repeat Expansion Disorders
